Abstract: . . .  consecutive individuals with a first or recurrent VTE. A separation could be made from the table in individuals with a first VTE at study entry C:\Documents and Settings\zzz6\Desktop\CLINICAL VALIDITY USE THIS.doc Page 25 and individuals with recurrent VTE at study entry. The number of individuals who had one venous thrombosis at study entry was 393. Not enough information was available to make the calculations for this particular group separately. Inclusion criteria: Age older than 18 years, absence of a known anticoagulation defect, absence of cancer, no other reasons for long-term treatment with antithrombotic drugs. Use of OAC: De . . .
. . .  who were referred to two specialized thrombosis centers. Inclusion criteria: Those with normal thrombophilia screening or carriers of the G20210A mutation. Exclusion if other thrombotic defects, cancer or myeloproliferative diseases, autoimmune disorders, or longer than 6 months or oral anticoagulant therapy after the first deep vein thrombosis . Information on use of OAC is missing. Modifiers: Stratification of recurrences according to the circumstances of the first event (spontaneous or secondary) produced no substantial difference. The rate of recurrence was similar in men and in women. C:\Documents and Settings\zzz6\Desktop\CLINICAL VALIDITY USE THIS.doc . . .
. . .  after the first deep vein thrombosis . Information on use of OAC is missing. Modifiers: Stratification of recurrences according to the circumstances of the first event (spontaneous or secondary) produced no substantial difference. The rate of recurrence was similar in men and in women. C:\Documents and Settings\zzz6\Desktop\CLINICAL VALIDITY USE THIS.doc  . . .
. . .  first deep vein thrombosis . Information on use of OAC is missing. Modifiers: Stratification of recurrences according to the circumstances of the first event (spontaneous or secondary) produced no substantial difference. The rate of recurrence was similar in men and in women. C:\Documents and Settings\zzz6\Desktop\CLINICAL VALIDITY USE THIS.doc  . . .
--3000,4,375,2617,55025